-
公开(公告)号：US20220233682A1
公开(公告)日：2022-07-28
申请号：US17573806
申请日：2022-01-12
IPC分类号： A61K39/215 , A61K39/21 , A61K39/205 , A61K39/39 , A61P31/14
摘要： The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include a spike protein from the Beta variant of SARS-Cov-2.
-
公开(公告)号：US11248026B2
公开(公告)日：2022-02-15
申请号：US15683355
申请日：2017-08-22
IPC分类号： A61K39/12 , A61P31/22 , C07K14/005 , A61K39/245 , A61K39/00
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US09777043B2
公开(公告)日：2017-10-03
申请号：US14357423
申请日：2012-11-09
IPC分类号： C07K14/00 , C07K14/005 , A61K39/245 , A61K39/00
CPC分类号： C07K14/005 , A61K39/245 , A61K2039/5258 , A61K2039/70 , C07K2319/00 , C07K2319/03 , C12N2710/16134 , C12N2740/13023 , C12N2760/20234
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US11253587B2
公开(公告)日：2022-02-22
申请号：US17218148
申请日：2021-03-30
IPC分类号： A61K39/12 , A61K39/00 , C12N7/00 , C07K14/005 , A61K39/21 , A61K39/215
摘要： The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
-
公开(公告)号：US20210353741A1
公开(公告)日：2021-11-18
申请号：US17218148
申请日：2021-03-30
IPC分类号： A61K39/215 , C12N7/00
摘要： The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
-
公开(公告)号：US20180289794A1
公开(公告)日：2018-10-11
申请号：US15795678
申请日：2017-10-27
摘要： The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.
-
公开(公告)号：US20230272013A1
公开(公告)日：2023-08-31
申请号：US17670052
申请日：2022-02-11
IPC分类号： C07K14/005 , A61K39/245
CPC分类号： C07K14/005 , A61K39/245 , A61K2039/70
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US20140308308A1
公开(公告)日：2014-10-16
申请号：US14357423
申请日：2012-11-09
IPC分类号： C07K14/005 , A61K39/245
CPC分类号： C07K14/005 , A61K39/245 , A61K2039/5258 , A61K2039/70 , C07K2319/00 , C07K2319/03 , C12N2710/16134 , C12N2740/13023 , C12N2760/20234
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
摘要翻译： 本公开提供了可用于治疗HCMV感染的组合物和方法。 如本文所述，组合物和方法基于免疫原性组合物的开发，其包括包含一种或多种莫洛尼鼠白血病病毒（MMLV）核心蛋白的病毒样颗粒（VLP），并且包括一种或多种HCMV表位，例如 例如，来自HCMV包膜糖蛋白gB和/或gH和/或凝胶蛋白pp65。 除此之外，本发明包括认识到抗原（例如，包膜糖蛋白和结构蛋白）的组合可以导致有益的免疫应答，例如包括体液应答（例如产生中和抗体）和细胞 反应（例如T细胞活化）。
-
公开(公告)号：US10456460B2
公开(公告)日：2019-10-29
申请号：US15795678
申请日：2017-10-27
IPC分类号： A61K39/12 , C12N7/00 , C07K14/005 , A61K39/00
摘要： The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.
-
公开(公告)号：US20170349634A1
公开(公告)日：2017-12-07
申请号：US15683355
申请日：2017-08-22
IPC分类号： C07K14/005 , A61K39/245 , A61K39/00
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.02 秒)
